pharmaceuticals

The United States Federal Trade Commission and the New York Attorney General's office are suing Vyera Pharmaceuticals LLC and former CEO Martin Shkreli for anti-competitive practices. What Happened Vyera, formerly known as Turing Pharmaceuticals, led by Shkreli, attempted to stifle...

As technology pours into the logistics industry and illuminates supply chain blind spots, opportunities for efficiency and profit abound.  The pharmaceutical industry, for instance, loses at least $15 billion of product each year to temperature deviations that force cargo disposal. When taking...

Maritime, air and overland trade routes into Europe are being piggybacked by criminal gangs deploying the latest digital supply chain technologies to help meet mushrooming demand for illegal drugs across the European Union (EU), according to a major new report examining the continent's illicit...

This article is from Benzinga’s Partner Content team The U.S. equities universe is a lot larger than most people realize. While there are over 6,000 stocks that trade on the NYSE and Nasdaq—the two largest U.S. exchanges—U.S. investors actually have access to over 10,000...

Following the recent inauguration of a pharmaceutical facility at Paris Charles de Gaulle Airport, the only facility owned by a ground handler dedicated to pharmaceuticals at the airport, air cargo handler Worldwide Flight Services (WFS) has opened a pharma facility at Copenhagen Airport. France...

Positive top-line results from a competitor’s prostate cancer drug trial led Bank of America to downgrade Clovis Oncology Inc (NASDAQ: CLVS). The Analyst Bank of America's Tazeen Ahmad downgraded Clovis Oncology from Buy to Neutral while lowering the price target from $13 to $7. The...

Health and Human Services Secretary Alex Azar and the Food and Drug Administration announced Wednesday that the Trump administration has dropped a long-standing resistance to importing drugs and outlined a plan that could eventually allow the importation of some cheaper prescription drugs from...

Morgan Stanley downgraded Pfizer Inc (NYSE: PFE) Tuesday after the drug company announced the spinoff of its Upjohn division on Monday, sending its stock downward. Shares of Mylan NV (NASDAQ: MYL), which merged with Upjohn, were moving in the other direction. The Analyst...

A U.S. federal judge ruled against a proposal that pharmaceutical companies need to disclose wholesale prices for their products in T.V. advertising, Reuters reported. What Happened The U.S. Department of Health and Human Services Secretary Alex Azar disclosed a new rule in early May which would...

The biotechnology space is an exciting one with incredible potential for investors. Moreover, due to the fact that several catalysts take place from the time a new discovery is made to the time a new drug is ready to be commercialized, the potential for big gains in value over a relatively short...

Officials from Britain and the United States signed mutual recognition agreements (MRAs) covering pharmaceuticals and telecommunications equipment, electromagnetic compatibility for information and communications technology products. Mutual recognition agreements are most often bilateral agreements...

TEVA Pharmaceutical Industries (NASDAQ: TEVA)'s fundamentals have substantially improved over the last few months, giving the stock a more balanced risk-reward profile, according to Leerink.  The Analyst Leerink analyst Ami Fadia upgraded TEVA Pharmaceutical from Underperform to Market...

Sanofi SA (ADR) (NYSE: SNY), is approaching a growth inflection point, according to Bank of America Merrill Lynch. The sell-side firm is projecting 6-percent earnings per share growth for the pharmaceutical company.  The Analyst Analyst Graham Parry upgraded Sanofi from Neutral to Buy and...

Initial reports of a pending M&A deal involving Shire PLC (ADR) (NASDAQ: SHPG) dates back to late March, when The Wall Street Journal reported that Japan-based Takeda Pharmaceuticals was interested in the Ireland-based pharmaceutical giant. The two companies reached a merger agreement Tuesday...

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced an encouraging update on etrasimod, its drug candidate for the treatment of autoimmune diseases like ulcerative colitis. What Happened Arena Pharmaceuticals reported topline Phase 2 results from an ongoing trial of etrasimod called OASIS...